Trial Profile
Consolidative Ipilimumab and Nivolumab With Thoracic Radiotherapy After Platinum Based Chemotherapy for Patients With Extensive-Stage Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 14 Feb 2022 Planned End Date changed from 1 Apr 2022 to 1 Dec 2022.
- 10 May 2018 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.